ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Sign Up

Already a member? Sign in

Top Brokers

More Brokers

Market Data
News
Trading Tools
Markets
Discover

Hot Features

Follow Feed

Connect with traders and investors in our Follow Feed community.

Options Flow

Explore comprehensive options data and use advanced filters with Options Flow.

Monitor

Organize and monitor your stock and asset watchlist with Monitor.
AI Sign In Premium IconPremium Help Menu
FTSE 100
8,139.71
0.03%
Dow Jones
42,946.35
-0.88%
Gold vs US Dollar
2,617.22
-0.59%
Brent Oil
73.465
0.79%
Bitcoin
94,519.28
-1.22%
Pepperstone
Advertisement
Registration Strip Icon for monitor Customisable watchlists with full streaming quotes from leading exchanges, such as LSE, NASDAQ, NYSE, AMEX, Bovespa, BIT and more.
Get Started
  1. Home
  2. Investing
  3. Stocks
  4. USA
  5. NASDAQ
  6. ContraFect Corporation (CFRX)

  7. ContraFect Corporation (CFRX) News

ContraFect (CFRX)

ContraFect Corporation
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:CFRX
DateTimeSourceHeadlineSymbolCompany
14/02/202419:24Edgar (US Regulatory)Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend]NASDAQ:CFRXContraFect Corporation
15/11/202321:41Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
08/11/202321:30Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
03/11/202321:08Edgar (US Regulatory)Form 424B3 - Prospectus [Rule 424(b)(3)]NASDAQ:CFRXContraFect Corporation
03/11/202304:16Edgar (US Regulatory)Form EFFECT - Notice of EffectivenessNASDAQ:CFRXContraFect Corporation
30/10/202321:24Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
24/10/202320:06Edgar (US Regulatory)Form S-1 - General form for registration of securities under the Securities Act of 1933NASDAQ:CFRXContraFect Corporation
23/10/202320:05Edgar (US Regulatory)Form DEFA14A - Additional definitive proxy soliciting materials and Rule 14(a)(12) materialNASDAQ:CFRXContraFect Corporation
16/10/202311:30GlobeNewswire Inc.ContraFect Announces FDA Clearance of CF-370 IND Application to Proceed With Phase 1 Clinical StudyNASDAQ:CFRXContraFect Corporation
29/09/202315:15Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
25/09/202312:00Edgar (US Regulatory)Form DEF 14A - Other definitive proxy statementsNASDAQ:CFRXContraFect Corporation
19/09/202312:30GlobeNewswire Inc.ContraFect to Present at the ASM/ESCMID Joint Conference on Drug DevelopmentNASDAQ:CFRXContraFect Corporation
18/09/202311:30GlobeNewswire Inc.ContraFect Announces Submission of IND Application to the FDA for its Development Candidate CF-370NASDAQ:CFRXContraFect Corporation
14/09/202320:05Edgar (US Regulatory)Form PRE 14A - Other preliminary proxy statementsNASDAQ:CFRXContraFect Corporation
28/08/202312:00GlobeNewswire Inc.ContraFect to Present at the World Anti-Microbial Resistance Congress 2023NASDAQ:CFRXContraFect Corporation
18/08/202321:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
14/08/202320:18Edgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:CFRXContraFect Corporation
14/08/202320:10Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
14/08/202312:30GlobeNewswire Inc.ContraFect Reports Second Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
25/07/202320:33Edgar (US Regulatory)Form 8-K - Current reportNASDAQ:CFRXContraFect Corporation
27/06/202312:30GlobeNewswire Inc.ContraFect Enters Into a Warrant Exercise Transaction for Proceeds of $9.6 MillionNASDAQ:CFRXContraFect Corporation
27/06/202312:01Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
20/06/202312:59GlobeNewswire Inc.ContraFect Data Presentations at ASM Microbe 2023 Demonstrate the Power of the Company’s Proprietary Platform to Discover New Agents Targeting Antibiotic-Resistant Gram-negative PathogensNASDAQ:CFRXContraFect Corporation
08/06/202320:01GlobeNewswire Inc.ContraFect to Present New Data Demonstrating the Potential Efficacy of Its Engineered Lysins Against Antibiotic-Resistant Pathogens at ASM Microbe 2023NASDAQ:CFRXContraFect Corporation
16/05/202310:03Edgar (US Regulatory)Current Report Filing (8-k)NASDAQ:CFRXContraFect Corporation
15/05/202320:28Edgar (US Regulatory)Quarterly Report (10-q)NASDAQ:CFRXContraFect Corporation
15/05/202312:00GlobeNewswire Inc.ContraFect Reports First Quarter 2023 Financial Results and Provides Business UpdateNASDAQ:CFRXContraFect Corporation
04/05/202310:05Edgar (US Regulatory)Notice of Effectiveness (effect)NASDAQ:CFRXContraFect Corporation
28/04/202320:21Edgar (US Regulatory)Securities Registration Statement (simplified Form) (s-3/a)NASDAQ:CFRXContraFect Corporation
26/04/202313:00GlobeNewswire Inc.ContraFect Announces First Patient Dosed in the Phase 1b/2 Study of Exebacase in Patients with Chronic Prosthetic Joint Infections of the KneeNASDAQ:CFRXContraFect Corporation
 Showing the most relevant articles for your search:NASDAQ:CFRX

Your Recent History

LSE
SYME
Supply@me Capital
LSE
AAZ
Anglo Asian Mining
LSE
VAST
Vast Resources
LSE
ZED
Zenova
LSE
GEX
Georgina Energy
LSE
UPS
LSE
TRP
Tower Resources
LSE
GDR
Genedrive
LSE
RPI
Raspberry Pi
LSE
SRT
Srt Marine Systems
LSE
VTY
Vistry
LSE
BIRD
Blackbird
LSE
BARC
Barclays
LSE
ZEN
Zenith Energy
LSE
LLOY
Lloyds Banking
LSE
UJO
Union Jack Oil
Delayed Upgrade Clock
    ADVFN Logo
    InvestorsHub

    United Kingdom
    Company
    Business
    Popular
    Get The App
    App Store
    Google Play

    Support: +44 (0) 203 8794 460 | support@advfn.com

    By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions

    © 2024 ADVFN PLC - All Rights Reserved

    Go Ad-Free

    Subscribe to Ad free and enjoy an ad-free experience

    No Ads

    Try Now

    Keep the Ads